<p>Pulse Biosciences, Inc（纳斯达克代码：PLSE - 获取免费报告）的股票在周五交易中下跌了 6.5%。该公司的股价最低曾达到 22.78 美元，最后交易价格为 23.4450 美元。交易期间大约成交了 63,161 股，较平均每日成交量 351,048 股下降了 82%。该股票此前收盘价为 25.08 美元。</p>
<p>获取 <strong>Pulse Biosciences</strong> 的提醒：</p>
<h2>Pulse Biosciences 新闻汇总</h2>
<p>以下是本周影响 Pulse Biosciences 的主要新闻：</p>
<ul>
<li>积极情绪：商业更新强调了 nPulse™系统的强劲临床/运营结果——在 6 个月内的心房颤动自由率为 100%，另一个队列的程序成功率为 96%，这支持了纳秒 PFA 平台的商业和临床潜力。Pulse Biosciences 发布商业更新及 2025 年第四季度和全年财务结果</li>
<li>积极情绪：Pulse 的每股收益（EPS）超出预期（报告亏损 0.26 美元，市场共识为-0.32 美元），这降低了相对于市场预期的短期盈利风险。投资者通常将 EPS 超出预期视为情绪的支持。Pulse Biosciences Inc（PLSE）报告第四季度亏损，超出收入预期</li>
<li>积极情绪：管理层将在第 46 届 TD Cowen 医疗会议上进行演讲——这是一个增加投资者可见度、更新指导/路线图的机会，如果管理层提供积极的商业化更新，可能会激发兴趣。Pulse Biosciences 将在第 46 届 TD Cowen 医疗会议上进行演讲</li>
<li>中性情绪：完整的第四季度财报电话会议记录和重建可用（Seeking Alpha，MSN）；对希望了解管理层对商业化时间表、报销和现金流的语气的投资者有用，但没有新的头条新闻。Pulse Biosciences, Inc.（PLSE）2025 年第四季度财报电话会议记录</li>
<li>中性情绪：分析师/市场预览（例如，Benzinga）讨论盈利潜力和长期机会；这些是背景信息，而不是直接催化剂。Pulse Biosciences 盈利潜力的初步观察</li>
<li>消极情绪：收入大幅低于预期——报告的收入基本持平/负增长，与市场预期（公司报告的收入与预期的约 23 万美元相比微乎其微），这可能导致短期卖压，尽管 EPS 超出预期。Pulse Biosciences 财报及新闻稿摘要</li>
<li>消极情绪：在两份文件中披露的内部人士股票出售（约 470.6 万美元和约 472.6 万美元）——显著的内部人士出售可能被市场解读为负面，并可能加大下行压力。Pulse Biosciences NASDAQ：PLSE 内部人士出售 470,600.00 美元的股票 Pulse Biosciences NASDAQ：PLSE 内部人士出售 472,600.00 美元的股票</li>
</ul>
<h2>分析师评级上调与下调</h2>
<p>几家研究公司最近对 PLSE 发表了评论。瑞穗证券在 2 月 6 日的研究报告中将 Pulse Biosciences 的目标价设定为 30.00 美元。Oppenheimer 在周五重申了 “跑赢大盘” 的评级，并将 Pulse Biosciences 的目标价设定为 30.00 美元。最后，Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Pulse Biosciences 的 “卖出（d-）” 评级。两位股票研究分析师对该股票给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，平均目标价为 30.00 美元。</p>
<p><strong>阅读我们关于 Pulse Biosciences 的最新报告</strong></p>
<h2>Pulse Biosciences 下跌 10.5%</h2>
<p>该公司的 50 日移动平均线为 16.21 美元，200 日移动平均线为 16.03 美元。公司的市值为 15.2 亿美元，市盈率为-19.81，贝塔值为 1.77。</p>
<p>Pulse Biosciences（纳斯达克代码：PLSE - 获取免费报告）最后一次公布季度财报是在 2 月 19 日。该公司报告的每股收益（EPS）为（0.26 美元），超出分析师的共识预期（0.32 美元）0.06 美元。该公司本季度的收入为（0.09）百万美元，而分析师的预期为 23 万美元。</p>
<h2>内部人士活动</h2>
<p>在相关消息中，内部人士 Kevin Patrick Danahy 于 2 月 17 日以每股 23.63 美元的平均价格出售了 20,000 股公司的股票，总价值为 472,600.00 美元。出售后，该内部人士直接持有公司 43,298 股，价值约为 1,023,131.74 美元。此次交易使其持股减少了 31.60%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此超链接访问。内部人士在上个季度出售了价值 1,876,200 美元的 80,000 股公司股票。内部人士持有公司 74.60% 的股份。</p>
<h2>机构资金流入与流出</h2>
<p>对冲基金和其他机构投资者最近修改了对该公司的持股。AlphaQuest LLC 在第二季度将其在 Pulse Biosciences 的股份增加了 184.5%。AlphaQuest LLC 现在拥有 8,864 股公司股票，价值 134,000 美元，此前在上个季度增持了 5,748 股。Westside Investment Management Inc.在第二季度增持了 Pulse Biosciences 的股份，增幅为 10.5%。Westside Investment Management Inc.现在拥有 64,290 股公司股票，价值 970,000 美元，此前在该期间增持了 6,135 股。Argo Wealth Advisory LLC 在第四季度购买了 Pulse Biosciences 的新头寸，价值约 387,000 美元。Quotient Wealth Partners LLC 在第四季度购买了 Pulse Biosciences 的新股份，价值 218,000 美元。最后，FourThought Financial Partners LLC 在第三季度购买了 Pulse Biosciences 的新股份，价值 355,000 美元。目前 76.95% 的股票由机构投资者持有。</p>
<h2>Pulse Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Pulse Biosciences, Inc 是一家临床阶段的生物电医学公司，开发和商业化基于其专有的组织纳米穿孔（TNP）平台的医疗设备。公司的核心技术，纳米脉冲刺激（NPS），向目标组织传递超短、高电压的电脉冲，触发细胞反应，而不会造成传统能量设备相关的热损伤。Pulse Biosciences 专注于皮肤科和美容医学的应用，在这些领域，控制性消融不必要的病变至关重要。</p>
<p>公司的旗舰产品 CellFX®系统旨在治疗多种良性和恶性皮肤病变，包括脂溢性角化病、非黑色素瘤皮肤癌以及各种表皮和真皮病变。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 Pulse Biosciences 更好的股票</li>
<li>有 500 美元？投资于 Elon 的人工智能大师计划</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>不到 1% 的美国人拥有这种被低估的资产——你应该拥有吗？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Pulse Biosciences 吗？</h2>
<p>在你考虑 Pulse Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Pulse Biosciences 并不在名单上。</p>
<p>虽然 Pulse Biosciences 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做空 - Direxion

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

PLSE

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Pulse Biosciences（纳斯达克代码：PLSE）的股价下跌 6.5%，至 23.4450 美元，交易量较平均水平下降 82%。尽管每股收益报告为-0.26 美元，但收入未能达到预期，实际为-0.09 百万美元，而预期为 0.23 百万美元。内部人士的抛售引发了担忧，总销售额超过 47 万美元。分析师的看法不一，瑞穗证券和奥本海默设定了 30 美元的目标价，而韦斯评级则给予 “卖出” 评级。该公司的市值为 15.2 亿美元，平均评级为 “持有”</p>

<p>Shares of Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) were down 6.5% during trading on Friday . The company traded as low as $22.78 and last traded at $23.4450. Approximately 63,161 shares were traded during trading, a decline of 82% from the average daily volume of 351,048 shares. The stock had previously closed at $25.08.</p>
<div class="lb-trans"><p>Pulse Biosciences, Inc（纳斯达克代码：PLSE - 获取免费报告）的股票在周五交易中下跌了 6.5%。该公司的股价最低曾达到 22.78 美元，最后交易价格为 23.4450 美元。交易期间大约成交了 63,161 股，较平均每日成交量 351,048 股下降了 82%。该股票此前收盘价为 25.08 美元。</p>
</div><p>Get <strong>Pulse Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Pulse Biosciences</strong> 的提醒：</p>
</div><h2>Pulse Biosciences News Roundup</h2>
<div class="lb-trans"><h2>Pulse Biosciences 新闻汇总</h2>
</div><p>Here are the key news stories impacting Pulse Biosciences this week:</p>
<div class="lb-trans"><p>以下是本周影响 Pulse Biosciences 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Business update highlighted strong clinical/operational results for the nPulse™ system — headline procedural success rates of 100% freedom from AF at 6 months and 96% procedural success in another cohort, which supports the commercial and clinical potential of the nanosecond PFA platform. Pulse Biosciences Reports Business Updates and Fourth Quarter &amp; Full Year 2025 Financial Results</li>
<li>Positive Sentiment: Pulse beat EPS expectations (reported loss of $0.26 vs. consensus -$0.32), which reduces near-term earnings risk relative to street estimates. Investors often view an EPS beat as supportive for sentiment. Pulse Biosciences Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates</li>
<li>Positive Sentiment: Management will present at the 46th Annual TD Cowen Healthcare Conference — an opportunity to increase investor visibility, refresh guidance/roadmap, and potentially catalyze interest if management provides positive commercialization updates. Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference</li>
<li>Neutral Sentiment: Full Q4 earnings call transcripts and reconstructions are available (Seeking Alpha, MSN); useful for investors who want management's tone on commercialization timelines, reimbursement, and cash runway but no new headline news. Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript</li>
<li>Neutral Sentiment: Analyst/market previews (e.g., Benzinga) discuss earnings potential and longer-term opportunity; these are background context rather than immediate catalysts. A Glimpse of Pulse Biosciences's Earnings Potential</li>
<li>Negative Sentiment: Revenue materially missed expectations — reported essentially flat/negative revenue versus street estimates (company reported minimal revenue vs. expected ~$0.23M), which likely drove near-term selling pressure despite the EPS beat. Pulse Biosciences Earnings &amp; Press Release Summary</li>
<li>Negative Sentiment: Insider stock sales disclosed in two filings (~$470.6k and ~$472.6k) — significant insider selling can be interpreted negatively by the market and may amplify downward pressure. Pulse Biosciences NASDAQ: PLSE Insider Sells $470,600.00 in StockPulse Biosciences NASDAQ: PLSE Insider Sells $472,600.00 in Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：商业更新强调了 nPulse™系统的强劲临床/运营结果——在 6 个月内的心房颤动自由率为 100%，另一个队列的程序成功率为 96%，这支持了纳秒 PFA 平台的商业和临床潜力。Pulse Biosciences 发布商业更新及 2025 年第四季度和全年财务结果</li>
<li>积极情绪：Pulse 的每股收益（EPS）超出预期（报告亏损 0.26 美元，市场共识为-0.32 美元），这降低了相对于市场预期的短期盈利风险。投资者通常将 EPS 超出预期视为情绪的支持。Pulse Biosciences Inc（PLSE）报告第四季度亏损，超出收入预期</li>
<li>积极情绪：管理层将在第 46 届 TD Cowen 医疗会议上进行演讲——这是一个增加投资者可见度、更新指导/路线图的机会，如果管理层提供积极的商业化更新，可能会激发兴趣。Pulse Biosciences 将在第 46 届 TD Cowen 医疗会议上进行演讲</li>
<li>中性情绪：完整的第四季度财报电话会议记录和重建可用（Seeking Alpha，MSN）；对希望了解管理层对商业化时间表、报销和现金流的语气的投资者有用，但没有新的头条新闻。Pulse Biosciences, Inc.（PLSE）2025 年第四季度财报电话会议记录</li>
<li>中性情绪：分析师/市场预览（例如，Benzinga）讨论盈利潜力和长期机会；这些是背景信息，而不是直接催化剂。Pulse Biosciences 盈利潜力的初步观察</li>
<li>消极情绪：收入大幅低于预期——报告的收入基本持平/负增长，与市场预期（公司报告的收入与预期的约 23 万美元相比微乎其微），这可能导致短期卖压，尽管 EPS 超出预期。Pulse Biosciences 财报及新闻稿摘要</li>
<li>消极情绪：在两份文件中披露的内部人士股票出售（约 470.6 万美元和约 472.6 万美元）——显著的内部人士出售可能被市场解读为负面，并可能加大下行压力。Pulse Biosciences NASDAQ：PLSE 内部人士出售 470,600.00 美元的股票 Pulse Biosciences NASDAQ：PLSE 内部人士出售 472,600.00 美元的股票</li>
</ul>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>Several research firms have recently commented on PLSE. Mizuho set a $30.00 price objective on Pulse Biosciences in a research note on Friday, February 6th. Oppenheimer reissued an &#34;outperform&#34; rating and set a $30.00 price target on shares of Pulse Biosciences in a report on Friday. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Pulse Biosciences in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of &#34;Hold&#34; and an average target price of $30.00.</p>
<div class="lb-trans"><p>几家研究公司最近对 PLSE 发表了评论。瑞穗证券在 2 月 6 日的研究报告中将 Pulse Biosciences 的目标价设定为 30.00 美元。Oppenheimer 在周五重申了 “跑赢大盘” 的评级，并将 Pulse Biosciences 的目标价设定为 30.00 美元。最后，Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Pulse Biosciences 的 “卖出（d-）” 评级。两位股票研究分析师对该股票给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，平均目标价为 30.00 美元。</p>
</div><p><strong>Read Our Latest Report on Pulse Biosciences</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Pulse Biosciences 的最新报告</strong></p>
</div><h2>Pulse Biosciences Trading Down 10.5%</h2>
<div class="lb-trans"><h2>Pulse Biosciences 下跌 10.5%</h2>
</div><p>The firm has a 50 day moving average of $16.21 and a 200-day moving average of $16.03. The company has a market cap of $1.52 billion, a P/E ratio of -19.81 and a beta of 1.77.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 16.21 美元，200 日移动平均线为 16.03 美元。公司的市值为 15.2 亿美元，市盈率为-19.81，贝塔值为 1.77。</p>
</div><p>Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.06. The company had revenue of ($0.09) million for the quarter, compared to analysts' expectations of $0.23 million.</p>
<div class="lb-trans"><p>Pulse Biosciences（纳斯达克代码：PLSE - 获取免费报告）最后一次公布季度财报是在 2 月 19 日。该公司报告的每股收益（EPS）为（0.26 美元），超出分析师的共识预期（0.32 美元）0.06 美元。该公司本季度的收入为（0.09）百万美元，而分析师的预期为 23 万美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部人士活动</h2>
</div><p>In related news, insider Kevin Patrick Danahy sold 20,000 shares of the business's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $23.63, for a total value of $472,600.00. Following the sale, the insider directly owned 43,298 shares in the company, valued at approximately $1,023,131.74. The trade was a 31.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Insiders sold 80,000 shares of company stock valued at $1,876,200 over the last quarter. Insiders own 74.60% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Kevin Patrick Danahy 于 2 月 17 日以每股 23.63 美元的平均价格出售了 20,000 股公司的股票，总价值为 472,600.00 美元。出售后，该内部人士直接持有公司 43,298 股，价值约为 1,023,131.74 美元。此次交易使其持股减少了 31.60%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此超链接访问。内部人士在上个季度出售了价值 1,876,200 美元的 80,000 股公司股票。内部人士持有公司 74.60% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入与流出</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the company. AlphaQuest LLC increased its stake in Pulse Biosciences by 184.5% during the second quarter. AlphaQuest LLC now owns 8,864 shares of the company's stock worth $134,000 after acquiring an additional 5,748 shares during the last quarter. Westside Investment Management Inc. boosted its holdings in shares of Pulse Biosciences by 10.5% in the 2nd quarter. Westside Investment Management Inc. now owns 64,290 shares of the company's stock worth $970,000 after purchasing an additional 6,135 shares during the period. Argo Wealth Advisory LLC bought a new position in shares of Pulse Biosciences during the 4th quarter valued at approximately $387,000. Quotient Wealth Partners LLC purchased a new stake in Pulse Biosciences during the 4th quarter valued at $218,000. Finally, FourThought Financial Partners LLC bought a new stake in Pulse Biosciences in the third quarter worth $355,000. 76.95% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近修改了对该公司的持股。AlphaQuest LLC 在第二季度将其在 Pulse Biosciences 的股份增加了 184.5%。AlphaQuest LLC 现在拥有 8,864 股公司股票，价值 134,000 美元，此前在上个季度增持了 5,748 股。Westside Investment Management Inc.在第二季度增持了 Pulse Biosciences 的股份，增幅为 10.5%。Westside Investment Management Inc.现在拥有 64,290 股公司股票，价值 970,000 美元，此前在该期间增持了 6,135 股。Argo Wealth Advisory LLC 在第四季度购买了 Pulse Biosciences 的新头寸，价值约 387,000 美元。Quotient Wealth Partners LLC 在第四季度购买了 Pulse Biosciences 的新股份，价值 218,000 美元。最后，FourThought Financial Partners LLC 在第三季度购买了 Pulse Biosciences 的新股份，价值 355,000 美元。目前 76.95% 的股票由机构投资者持有。</p>
</div><h2>Pulse Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Pulse Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.</p>
<div class="lb-trans"><p>Pulse Biosciences, Inc 是一家临床阶段的生物电医学公司，开发和商业化基于其专有的组织纳米穿孔（TNP）平台的医疗设备。公司的核心技术，纳米脉冲刺激（NPS），向目标组织传递超短、高电压的电脉冲，触发细胞反应，而不会造成传统能量设备相关的热损伤。Pulse Biosciences 专注于皮肤科和美容医学的应用，在这些领域，控制性消融不必要的病变至关重要。</p>
</div><p>The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.</p>
<div class="lb-trans"><p>公司的旗舰产品 CellFX®系统旨在治疗多种良性和恶性皮肤病变，包括脂溢性角化病、非黑色素瘤皮肤癌以及各种表皮和真皮病变。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Pulse Biosciences</li>
<li>Have $500? Invest in Elon’s AI Masterplan</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>Fewer Than 1% of Americans Own This Undervalued Asset — Should You?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Pulse Biosciences 更好的股票</li>
<li>有 500 美元？投资于 Elon 的人工智能大师计划</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>不到 1% 的美国人拥有这种被低估的资产——你应该拥有吗？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pulse Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Pulse Biosciences 吗？</h2>
</div><p>Before you consider Pulse Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Pulse Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Pulse Biosciences 并不在名单上。</p>
</div><p>While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Pulse Biosciences 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Pulse Biosciences (NASDAQ:PLSE)  Shares Down 6.5%   - Here's Why

Market Beat

Pulse Biosciences

Pulse Biosciences (NASDAQ:PLSE) 股价下跌 6.5% - 以下是原因